Therapeutics News and Research

RSS

VCU Massey pioneers clinical trial of novel GGT-1 inhibitor PTX-100

VCU Massey Comprehensive Cancer Center is the first site in the United States to be activated in a global Phase 2a clinical trial evaluating PTX-100 (AKA GGTI-2418), a first-in-class small molecule inhibitor of geranylgeranyl transferase-1 (GGT-1), for the treatment of cutaneous T-cell lymphoma (CTCL), a rare and often treatment-resistant T-cell lymphoma.

26 Jul 2025

Blocking nutrient scavenging weakens pancreatic tumor defenses

Cancer cells and tumors do not exist in a vacuum. Far from the isolation and self-sufficiency of the fictional Wakanda, tumors develop in and alter the nearby milieu of immune cells, connective tissue, blood vessels and a sea of proteins and carbohydrates that provide structure and other supportive functions.

24 Jul 2025

Different anti-PD-L1 antibodies show varied results in tumor growth inhibition

Immune checkpoint inhibitors (ICIs), a powerful form of immunotherapy, have revolutionized cancer treatment by unleashing the body's own immune system to fight tumors.

24 Jul 2025

New redox-sensitive pathway reveals how cells activate AMPK in response to metabolic stress

AMP-activated protein kinase (AMPK) plays a central role in maintaining energy balance in cells, especially under energy stress.

24 Jul 2025

Reactivating silent genes offers hope for Rett syndrome treatment

Researchers led by UC Davis Health scientist Sanchita Bhatnagar have developed a promising gene therapy that could treat Rett syndrome.

23 Jul 2025

Novel DNA plasmid therapy shows high success rate in treating chronic pain in dogs

Elenagen™, a novel DNA plasmid therapy that previously demonstrated high clinical benefit and low toxicity in cancer patients, has now shown significant promise in alleviating chronic pain demonstrating a 90% success rate.

23 Jul 2025

New collaborative effort harnesses AI to drive ALS drug discovery in Louisiana

Answer ALS is proud to announce the launch of a groundbreaking collaborative initiative aimed at accelerating AI-powered drug discovery for ALS and other neurodegenerative diseases.

23 Jul 2025

Intranasal insulin safely and effectively reaches key memory regions of the brain

A groundbreaking brain imaging study from Wake Forest University School of Medicine confirms a vital step toward new Alzheimer's disease treatments: Intranasal insulin, delivered via a simple nasal spray, safely and effectively reaches key memory regions of the brain in older adults.

23 Jul 2025

Probiotic bacteria found to reshape cell behavior in vitro

This study reveals how probiotic bacteria directly influence brain cell function, highlighting gut-brain communication and potential therapeutic applications.

23 Jul 2025

Cannabis and psychedelics rated most effective for symptom relief by eating disorder patients

A pioneering international survey of people living with eating disorders has found that cannabis and psychedelics, such as 'magic mushrooms' or LSD, were best rated as alleviating symptoms by respondents who self-medicated with the non-prescribed drugs.

22 Jul 2025

Mount Sinai researcher uncovers how the brain and body interact in aging and depression

In a comprehensive Genomic Press interview published in Brain Medicine today, Dr. Hamilton Se-Hwee Oh reveals groundbreaking insights into the complex dialogue between our brains and bodies that fundamentally shapes aging, depression, and neurodegenerative disease.

22 Jul 2025

New antibody therapy offers hope for fragile patients with Fanconi anemia

An antibody treatment developed at Stanford Medicine successfully prepared patients for stem cell transplants without toxic busulfan chemotherapy or radiation, a phase 1 clinical trial has shown.

22 Jul 2025

PhoreMost demonstrates new approach to rationalize molecular glue drug discovery

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced the publication of a study demonstrating the capabilities of its high-throughput GlueSEEKER platform to accelerate the design and development of novel molecular glue degraders.

22 Jul 2025

Muscle-derived vesicles heal damaged cells and reverse disease in new study

Researchers discovered that mitochondria-rich extracellular vesicles (Ti-mitoEVs) from skeletal muscle can deliver healthy mitochondria to damaged cells, restoring energy and promoting tissue repair in mice. The approach reversed acute muscle injury and chronic kidney disease, offering a promising new regenerative therapy.

21 Jul 2025